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Background: Breast cancer patients face several preference-sensitive treatment decisions. Feelings such as regret or
having had inadequate information about these decisions can significantly alter patient perceptions of recovery and
recurrence. Numerous objective measures of decision quality (e.g., knowledge assessments, values concordance
measures) have been developed; there are far fewer measures of subjective decision quality and little consensus
regarding how the construct should be assessed. The current study explores the psychometric properties of a
new subjective quality decision measure for breast cancer treatment that could be used for other preference
sensitive decisions.
Methods: 320 women aged 20–79 diagnosed with AJCC stage 0 – III breast cancer were surveyed at two cancer
specialty centers. Decision quality was assessed with single items representing six dimensions: regret, satisfaction,
and fit as well as perceived adequacy of information, time, and involvement. Women rated decision quality for their
overall treatment experience and surgery, chemotherapy, and radiation decisions separately. Principle components
was used to explore factor structure. After scales were formed, internal consistency was computed using Cronbach’s
alpha. The association of each of the four final scales with patient characteristics scores was examined by Pearson
correlation.
Results: For overall breast cancer treatment as well as surgery, chemotherapy, and radiation decisions, the six items
yielded a single factor solution. Factor loadings of the six decision items were all above .45 across the overall and
treatment-specific scales, with the exception of “Right for You” for chemotherapy and radiation. Internal consistency
was 0.77, 0.85, 0.82, and 0.78 for the overall, surgery, chemotherapy, and radiation decision quality scales, respectively.
Conclusions: Our measure of subjective appraisal of breast cancer treatment decisions includes 5 related elements;
regret and satisfaction as well as perceived adequacy of information, time, and involvement. Future research is needed
to establish norms for the measure as is further psychometric testing, particularly to examine how it is associated with
outcomes such as quality of life, psychological coping and objective decision quality.
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Patient appraisal of breast cancer treatment decisions is an
important component of psychological coping and quality
of life [1-4]. Breast cancer (BC) patients face numerous
complex and consequential decisions regarding diagnostic
and genetic testing, local and systemic treatment, and the
possibility of reconstructive surgery. The process of mak-
ing BC treatment decisions can engender anxiety and fear
in the immediate period following diagnosis. Over time,
feelings such as regret or having had inadequate informa-
tion, time or input about these important decisions can
significantly alter perceptions of recovery and recurrence
[5-7]. Decision satisfaction is particularly important in
breast cancer because many treatment decisions, such as
the choice to undergo mastectomy versus breast conserv-
ing surgery, are preference sensitive. That is, they are (or
at least should be) driven more by patient preferences and
values than any clear medical advantage [8-10]. There is a
need therefore, for valid measures to help researchers and
clinicians assess how patients perceive the quality of their
BC treatment decisions [11].
Approaches to measuring decision quality for BC can be
dichotomized into “objective” and “subjective” methods
[8,9,12]. Objective measures of decision-making generally
focus on quantifying the decision process. This includes
assessment of factors such as patient knowledge, e.g.,
awareness that breast conserving surgery and mastectomy
generally yield similar survival rates or the potential need
for chemotherapy following surgery The assumption is
that decisions made by informed patients are inherently
higher quality than those based on inaccurate or insuffi-
cient information [2,8,13,14]. Another component of ob-
jective assessment of treatment decisions entails rating the
concordance/dissonance between the patient’s preferred
decision making style, e.g., patient driven versus provider
driven, and how the treatment decisions were actually
made [1-4,9,13]. Concordance also includes how well the
selected treatments or tests match patients’ values or pref-
erences, e.g., a patient who desires to keep her natural
breast over other treatment factors should receive lumpec-
tomy [8]. Here again, the assumption is that higher con-
cordance between patient preferences and either the
decision process utilized or the treatment and tests re-
ceived represents a higher quality decision [13,14]. And fi-
nally, while the ability to quantify the nature of the
decision (e.g., high or low) is a strength of objective mea-
sures, obtaining a true objective assessment of decision
making is often challenging (e.g., determining if the deci-
sion was values concordant) and can bleed over into more
qualitative assessment.
Subjective assessment of decision quality, on the other
hand, focuses on patients’ appraisal of the decision making
process. Subjective decisional quality has been operationalized
using several dimensions, most commonly satisfaction andregret [13,15-18]. Although there is no “correct” response
for this type of measure, as there is in objective measures,
the assumption is that higher subjective satisfaction and
lower regret represent higher quality decisions. Aspects of
“objective” quality decisions can be incorporated into sub-
jective measures by querying patient perceptions of the
adequacy of their knowledge, their level of involvement, or
the amount of time they had to make their decisions
[9,15-17,19-23]. Rather than focusing on what patients
know, subjective knowledge assessment addresses their
perceived adequacy of information, which may be high
even absent key information or low even when key infor-
mation is known. The same holds true for subjective rat-
ing of the degree of involvement and the amount of time
they had to make their decisions. Objective and subjective
assessments appear to tap different dimensions of decision
quality, as there is often only a weak association between
subjective ratings of knowledge and actual knowledge
[24,25]. Little has been reported on the association be-
tween objective and subjective concordance.
Although the distinction between objective and subject-
ive elements of breast cancer (or more broadly, medical)
decision making has not been previously proposed, this di-
chotomy mirrors the distinction between the deliberation
process and the determination of decisions proposed by
Elwyn and Miron-Shatz [26]. Specifically the authors note
(ibid page 143), “we need to evaluate both the decision
making (the perceived or observed process) and the deter-
mination (whether or not the decision itself is considered
“good”)”. Our proposed measure similarly distinguishes
between the objective processes used in making the deci-
sion and the subsequent subjective evaluation of that deci-
sion, with a focus on the latter. Similarly, Sepucha et al.,
delineate two primary dimension for evaluating decision
aids, 1) the quality of the decision-making process and, 2)
the quality of the choice [27].
Numerous objective knowledge and concordance mea-
sures, particularly for the purpose of evaluating patient
decision aids [8,27,28], have been reported [9,12,16,19]
including the Decisional Conflict Scale [29,30] and some
consensus regarding the content of these measures has
emerged [27]. There are, however, fewer measures of
subjective decision quality and even less consensus re-
garding how the construct should be assessed. We could
find only one measure that exclusively tapped subjective
decisional quality (SDQ); the Satisfaction With Decision
(SWD) scale by Holmes-Rovner et al. [31]. This measure
however, only assesses positive aspects of decision quality
(DQ), i.e., it contains no negatively framed items such as
regret and does not assess satisfaction with how much in-
volvement and time the patient perceives they had in mak-
ing their decision, both of which have been proposed as
key elements of a quality decision [11]. The proposed
measure evaluated herein, includes these elements.
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chometric properties of a new subjective quality decision
measure for breast cancer treatment decision quality that
could be applied to other preference sensitive decisions.
The goal was to produce a brief yet comprehensive meas-
ure that can be used by researchers and practitioners.
Conceptually, our measure was also informed by
Self-Determination Theory (SDT), which distinguishes
between controlled and autonomous motivation [32-34].
SDT posits that behavior change decisions that respect
and support the patient’s autonomy and competence are
more likely to be perceived as higher quality than deci-
sions that leave the patient feeling pressured or compli-
ant (i.e., controlled motivation). Specifically, the item
regarding adequate knowledge is intended to tap compe-
tence, whereas items related to involvement and time
are intended to tap the degree of autonomy in the deci-
sion making process.
Based on our theoretical framework and our team’s ex-
perience [17] as well as a review of the literature and ex-
tant measures [4,7,20,21] we generated six potential
dimensions of subjective decision quality: regret, satis-
faction, and fit (operationalized by asking if the treat-
ment received was “right for you”) as well as perceived
adequacy of information, time, and involvement in mak-
ing their breast cancer treatment decisions. Decision
quality was assessed for the patient’s overall treatment
decisions, as well as for surgery, chemotherapy, and radi-
ation decisions separately.
Methods
Study sample and data collection
The target sample was women aged 20–79 who were di-
agnosed with American Joint Committee on Cancer
(AJCC) stage 0 – III breast cancer within the previous
18 months. Participants were recruited from Memorial
Sloan-Kettering Cancer Center (MSKCC) in New York
and from Emory Midtown Hospital, the Winship Cancer
Institute of Emory University, and Grady Memorial Hos-
pital in Georgia between June and September 2013.
Based on sample size calculations for both precision of
prevalence estimates (there were other items being
tested on the pilot survey not reported here) as well as
sample adequacy for factor analysis, we set a quota sam-
ple of 250 completed surveys and over-recruited to en-
sure adequate statistical power.
At MSKCC, eligible breast cancer patients were approached
in-clinic and asked to complete the survey. Patients who
met the inclusion criteria were identified by examining the
clinic schedule for the upcoming day and when feasible,
all eligible patients who showed up were approached.
These women were given the option to take the survey
home to complete if requested. A $10 incentive was pro-
vided to respondents upon completion of their survey.Individuals who did not respond received a reminder call,
if applicable, re-approached if they had a return visit to
the clinic during the piloting timeframe.
At the Georgia sites, eligible breast cancer patients
were identified by clinic records and mailed a survey
packet which included a $10 pre-incentive. Reminder
postcards and follow-up phone calls were made to non-
responders and second survey packets (with no second
incentive) were mailed as needed. The institutional re-
view boards of the University of Michigan, MSKCC, and
Emory University approved all study procedures and
materials and all participants gave their informed con-
sent prior to their inclusion in the study.
The response rate was 77.8% (214 of 275) in New York
and 56.7% (140 of 247) in Georgia, for a combined re-
sponse rate of 67.8% (354/522). We excluded from all
analyses 30 patients who were more than 18 months
after diagnosis (to maximize recall accuracy) and four
who had completely missing data, leaving a final sample
of 320. For factor and internal consistency analysis by
treatment modality, which required all items to be com-
pleted, the final sample size was 286, 286, 195, and 247,
for the overall treatment experience (hereafter referred
to as ‘overall”), surgery, chemotherapy, and radiation
scales respectively. In addition, when computing scale
means, we excluded those who had two or more missing
items as well as those who indicated that the procedure
was not offered. There were 22, 25, 113, and 65 surveys
that were excluded from the overall, surgery, chemother-
apy and radiation therapy scales, respectively for these
reasons. Thus, the final sample size for scale means was
298, 295, 207, and 255, for the overall, surgery, chemo-
therapy, and radiation scales.
The number endorsing “not offered” across the six items
for overall treatment ranged from 2 to 8, for surgery, 7 to
12, for radiation, 47 to 57, and for chemotherapy, 83 to
102. The skip rate across the six items for overall treatment
ranged from 2 to 8, for surgery 2 to 6, for radiation, 5 to 12,
and for chemotherapy 3 to 6 respondents. Data not shown.
Measures
Patient characteristics
Participants were asked about their age (dichotomized
around the median of 58 years), race, ethnicity, and level
of education (collapsed into high school or less, some
college, or college or higher) as well as the amount of
time (in months) since their breast cancer diagnosis (di-
chotomized as less than or equal to or greater than
12 months). We also asked yes/no questions to ascertain
whether or not they had received various tests or treat-
ments, specifically breast MRI, imaging tests (bone scan,
PET scan, or CT scan), BRCA genetic testing, the 21-
gene assay (Oncotype DX®), lumpectomy, mastectomy,
radiation therapy, and chemotherapy.
Table 2 Sample description
Mean/N Range/%
Age (mean (range)) 57.3 (29–79)
Months since diagnosis (mean (range)) 11.6 (1–18)
Race/Ethnicity (%)
White 234 74.3
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Decision quality was assessed initially with six dimen-
sions, each comprising one item. For each dimension we
asked the respondent to rate “overall treatment for your
breast cancer” as well as their decision about “which
type of surgery to have”, “whether or not to have chemo-
therapy”, and “whether or not to have radiation therapy”.
The overall item was placed before surgery, chemother-
apy, and radiation items for the information, involve-
ment, and satisfaction sections of the survey and
afterwards for the “right for you”, time, and regret sec-
tions. The six dimensions were assessed as described in
Table 1 below:
For adequacy of information, time, and involvement
we recoded values in two ways. First we recoded values
5 to 7 into 3 to 1, respectively, as we considered both
“not enough“ and “too much” an equally low quality de-
cision compared to “just right”, which was given the
highest value of 4. Next, we recoded these 1 to 4 values
to match the seven point scaling used in the remaining
three items, so that (1 = 1) (2 = 3) (3 = 5) and (4 = 7). In
addition, the regret item was reverse coded so that for
all items and scale scores higher values indicated higher
subjective decision quality.
Analyses
Principle components analysis was used to explore factor
structure and determine the appropriate number of factors.
We considered retaining factors with Eigen values >1.0.
We used item loading values of .45 or higher as indication
that the item should be retained in the final scale. After
scales were formed we computed internal consistency
using Cronbach’s alpha, and reported the alpha with each
item removed. The association of each of the four final
scale scores was examined by Pearson correlation. In
addition to exploring item-level psychometrics we also ex-
plored the association of scale scores for decisions regard-
ing surgery, chemotherapy, and radiation as well as the
association of mean scale scores by patient characteristicsTable 1 Decision quality instrument
a. How “right for you” were the following decisions?*
b. How much information did you have for the following decisions?+
c. How much time did you have for the following decisions?+
d. How much involvement did you have in the following decisions?+
e. How much regret do you have about the following decisions?^
f. How satisfied are you with the following decisions?^
*Rated on a 7-point scale anchored with: Not at all right for me (1), Neutral (4),
and Completely right for me (7).
+Rated on a 7-point scale anchored with: Not enough (1), Just Right (4), and
Too Much (7).
^Rated on a 7-point scale anchored with: No regret/Not at All Satisfied (1),
Some regret/Somewhat Satisfied (4), and A lot of regret/Totally Satisfied (7).
Bolded item is reverse-coded.
N/A option also included for all items.using a t-test. All analyses for this paper were generated
using SAS software.
Results
As shown in Table 2, the mean age of the sample was
57.3 years (range of 29–79). Mean months since breast
cancer diagnosis was 11.6 (range of 1–18 months). The
sample was 74% white, 18% black, 4% Asian, 3% His-
panic, and 1% American Indian. Most (90%) had at least
some college education. In terms of breast cancer treat-
ment, 73% had lumpectomy (breast conserving surgery),
31% had mastectomy, 68% had radiation therapy, 43%
had chemotherapy, 23% had surgery on the unaffected
breast (contralateral mastectomy), and 77% had lymph
nodes removed. There were five individuals who re-
ported neither surgery option and 18 who reported hav-
ing both types of surgery (likely because these patients
had a mastectomy following a lumpectomy with unclear
margins) which explains why the numbers for breast
conserving surgery and mastectomy do not add up
to 100%.
For overall BC treatment decisions, as well as for sur-
gery, chemotherapy, and radiation decisions separately,
the principal components analysis indicated a single fac-
tor solution, i.e., only one Eigen value greater than 1.0,
and in each case the Eigen value for the single factor
exceeded 2.4. As shown in Table 3, factor loadings of the
six items were generally consistent across the overall and
treatment-specific scales. The only item that did not meet
the criteria for inclusion, based on factor loading >0.45,Black 57 18.1
Asian 13 4.1
Hispanic 8 2.5
American Indian 3 1.0
Education (%)
HS or less 32 10.0
Some college 100 31.4
College or greater 187 58.6
Treatment received (%)















“Right for you” 0.49 0.50 0.25 0.25
Information 0.63 0.76 0.79 0.70
Time 0.77 0.81 0.81 0.65
Involvement 0.57 0.77 0.83 0.72
Regret 0.67 0.68 0.64 0.70
Satisfaction 0.59 0.72 0.73 0.74
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scales.
Internal consistency (i.e., alpha) was 0.77, 0.85, 0.82,
and 0.78 for the overall, surgery, chemotherapy, and ra-
diation decision quality scales, respectively. The removal
of “right for you’ slightly increased alpha for the chemo-
therapy and radiation scales. See Table 4.
The three treatment-specific decision scale scores,
computed from the means of the six items, formed a
single factor with an eigenvalue of 1.75. The factor load-
ings for the three treatment-specific subscales on this
single factor were .75, .76 and .79, for surgery, chemo-
therapy, and radiation, respectively. The correlations of
the three subscale scores of decision quality with the
overall decision quality score were .75, .70, and .74, re-
spectively, for surgery, chemotherapy, and radiation.
Data not shown.
Across the six items between 70% and 89% of respon-
dents answered with the most positive category, i.e., com-
pletely right for me, no regret, or totally satisfied for the
right for me, regret, and satisfaction items respectively,
and “Just Right” for the information, involvement, and
time items. Data not shown. As shown in Table 5, overall
means for the four scales were, 6.45, 6.56, 6.33, and 6.55,
respectively, for overall treatment, surgery, chemotherapy,
and radiation. Mean scores for the surgery scale were sig-










Alpha with all items 0.77 0.85 0.82 0.78
Alpha if item removed
“Right for you” 0.76 0.85 0.86 0.81
Information 0.75 0.82 0.77 0.74
Time 0.71 0.81 0.76 0.75
Involvement 0.75 0.82 0.76 0.73
Regret 0.73 0.82 0.78 0.74
Satisfaction 0.74 0.81 0.77 0.72those less than 58 years. Race/Ethnicity was associated
with scores of the surgery and chemotherapy scales.
Specifically, African American women had significantly
(p < .05) lower scores than whites for surgery decision
quality and both African American and Hispanic women
had significantly (p > .05) lower scores than whites for
chemotherapy decision quality. Months since diagnosis,
procedures received (with one exception of surgery
scores by chemotherapy), and education were not related
to scale scores.
Discussion
The primary finding from these analyses is that our
measure of subjective appraisal of breast cancer treat-
ment decisions appears to comprise at least five related
dimensions. These five dimensions, regret and satisfac-
tion as well as adequacy of information, time, and in-
volvement appear to merit inclusion on the final scale
for the overall treatment as well as treatment-specific
scales (i.e., surgery, radiation, and chemotherapy). The
remaining element “Right for You”, was a candidate for
removal, based on factor loading and/or internal
consistency results for decisions regarding chemotherapy
and radiation. For overall treatment and surgery specific
decisions, however, it appears to merit inclusion. Al-
though for parsimony we recommend the five –item ver-
sion, for investigators assessing decision quality for
chemotherapy and radiation for breast cancer, inclusion
of the “right for you” item may be justified.
A second finding is that scores from the three
treatment-specific decisions scales correlated with over-
all decision quality in the range of .70 to .75, with sur-
gery exhibiting the highest correlation with the overall
score. This raises the question as to whether decision
quality should be assessed for each treatment separately
or only for the patient’s overall treatment experience.
On one hand, given these correlations, each treatment
appears to capture a somewhat independent picture of
decision quality. However if questionnaire space is lim-
ited and/or respondent burden is a particular concern,
measuring only the overall treatment experience may be
appropriate.
The overall means of the four scales were high; 6.3 or
higher (out of 7) and across the six items between 70%
and 89% of respondents answered with the most positive
category, i.e., “completely right for me”, “no regret”, and
“totally satisfied” for the right for me, regret, and satisfac-
tion items respectively, and “just right” for the informa-
tion, involvement, and time items. This positively skewed
distribution (i.e., ceiling effect) is consistent with numer-
ous prior studies both for decision ratings for breast
cancer [35-40] and other cancers [37,41,42]. These high
scores may be, at least in part, inflated by patient re-
sponse bias, e.g., patients’ desire/need to feel good about
Table 5 Scale means by patient demographic and health factors
Overall Surgery Chemotherapy Radiation
N Mean N Mean N Mean N Mean
Scale mean 298 6.45 295 6.56 207 6.33 255 6.55
Age
< 58 148 6.40 147 6.411 114 6.25 122 6.52
> =58 150 6.49 148 6.701 193 6.44 133 6.58
Months since diagnosis
< 12 131 6.52 130 6.61 83 6.35 114 6.65
> =12 167 6.39 165 6.51 124 6.32 141 6.48
Race/Ethnicity
White 222 6.50 220 6.621 153 6.501,2 186 6.62
Black 50 6.24 49 6.201 33 5.761 45 6.33
American Indian 3 6.89 3 6.94 3 6.61 3 6.61
Asian 12 6.61 12 6.71 9 6.31 11 6.60
Hispanic 7 6.33 7 6.52 5 5.332 6 6.22
Education
HS or less 27 6.59 27 6.70 16 6.18 25 6.55
Some college 90 6.46 92 6.52 66 6.32 85 6.44
College or greater 181 6.42 176 6.55 125 6.36 145 6.62
Treatment received
Radiation therapy
Yes 206 6.46 206 6.56 143 6.36 210 6.59
No 88 6.43 85 6.54 61 6.28 42 6.36
Chemotherapy
Yes 128 6.37 133 6.381 132 6.26 112 6.49
No 166 6.50 159 6.701 73 6.46 140 6.61
Lumpectomy
Yes 219 6.48 215 6.61 145 6.37 214 6.57
No 75 6.38 76 6.42 59 6.25 39 6.52
Mastectomy
Yes 92 6.35 93 6.36 73 6.24 54 6.39
No 201 6.48 197 6.64 131 6.37 197 6.59
Values with common superscript differ significantly, t test p value < .05.
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much patient bias may influence decision quality scores is
an important area of research that cannot be answered
from our data. At one site surveys were administered in
person at the clinic and at the other site via mail. We
therefore examined scale means by study site but found
no significant differences for any of the four scales. Both
sites provide highly specialized breast cancer treatment
which could have biased scores upward. Whether survey-
ing patients from less specialized treatment centers would
have resulted in lower scores cannot be answered given
our study sample. Because this is a measure of subjective
decision quality, the values we observed may be consid-
ered inherently valid. Nonetheless, understanding how, ifat all, positive reporting bias and/or social desirability may
contribute to these scores remains an important area of
future research. Additionally, strategies to reduce positive
respondent bias, perhaps by altering our item stems or re-
sponse categories, merit attention.
The association of treatment-specific scores with over-
all decision quality scores was slightly stronger for sur-
gery than for chemotherapy and radiation. On one hand,
this may indicate that surgery experiences contribute
more to patients’ overall treatment appraisal than for
chemotherapy and radiation. On the other hand, because
surgery items were placed before chemotherapy and ra-
diation on the survey, it may be that ordering effects
contributed to these correlations. It should be noted that
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before surgery, chemotherapy, and radiation for informa-
tion, involvement, and satisfaction sections and after-
wards for “right for you”, time, and regret. When the
treatment-specific items preceded the overall items, the
mean of those items were correlated .67 with the mean
of the overall items, whereas when the treatment-
specific items followed the overall items the means were
correlated .75 with overall. Thus, a small ordering effect
for when the overall experience and treatment-specific
experiences were rated was evident in our sample. How-
ever, we did not vary the order of the surgery, chemo-
therapy, and radiation-specific items within each section,
so the impact of ordering effects on these dimensions
cannot be determined. Studies using random ordering of
all items may be useful to determine the full impact of
ordering on subject responses.
The initial psychometric properties of the scale is en-
couraging and, like other subjective rating scales, these
items may be considered inherently valid as they tap pa-
tient opinion or feeling. More expansive exploration re-
garding the validity of our decision quality measure,
however, is still warranted. This could include examining
how our measure may be associated with outcomes such
as quality of life, cancer-related anxiety, and persever-
ation and personality attributes such as social desirability
and optimism. It is somewhat noteworthy that scale
scores did not vary by time since diagnosis when we split
the sample at before/after 12 months. There is limited
work evaluating patients’ perceptions of breast cancer
treatment decisions for periods of time greater than one
year following diagnosis. Our survey did not include ob-
jective measures of decision quality, i.e., treatment
knowledge, values concordance, or decisional concord-
ance. Examining the relationship between objective and
subjective measures of decisional quality is encouraged.
We identified five to six dimensions of subjective deci-
sion quality that merited inclusion in our final scale;
however, other domains not measured here may also be
important components of decision quality. For example,
subjective difficulty, perseveration, conflict, decision
and/or social support, and anxiety related to cancer
treatment decisions may be important elements of qual-
ity decisions. They may load on the single dimension
identified here or they may yield additional factors. We
limited our scale to these six dimensions in part to keep
our scales brief, although this tradeoff may have come at
the cost of a more comprehensive and perhaps multi-
dimensional measure of the construct.
The study sample had relatively high levels of educa-
tion, with 90% having at least some college. Although
there were no differences in scale scores by level of edu-
cation, the sample size for the lower education segment
was small. How the scale may perform among a lowereducated and perhaps lower literacy population should be
examined. African American and Hispanic women had
lower decision quality scores for surgery and chemother-
apy than other groups. These differences remained after
adjustment for age and education. Elucidating why these
(and perhaps other) groups report low decision quality
merits exploration and may indicate potential opportun-
ities for intervention or policy change.
Finally, we did not conduct cognitive interviews with
patients for this psychometric pilot. Although we have
used these items and the corresponding response scales in
prior studies and obtained respondent feedback, it would
have been useful to conduct further pretesting including
cognitive interviewing to better elucidate how the items
are perceived. This is a priority for our future research.
Conclusions
Appraisal of BC treatment decisions is comprised of five
related elements; regret and satisfaction as well as per-
ceived adequacy of information, time, and involvement.
Assessment of the quality of each treatment decision (e.g.,
surgery, radiation, chemotherapy) separately is recom-
mended when feasible. Other domains not measured in
our study (e.g., subjective difficulty, conflict, or anxiety)
may also be important elements of a quality decision. The
initial promising psychometric properties of this brief
measure of subjective quality decision suggests it may be a
useful tool for understanding patients’ perceptions of their
breast cancer treatment decisions and could be used in
research and practice.
Future psychometric testing is encouraged, including
establishing norms for the scale as well as its convergent
and divergent validity by examining how the measure is
associated with other outcomes such as quality of life,
psychological coping, decisional conflict, objective deci-
sion quality, and perhaps even survival. Although we
tested the measure in the context of breast cancer treat-
ment, the scale may be applicable to assessing subjective
decision quality for other preference sensitive medical
decisions.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KR conceptualized and participated in the design of the study, assisted with
analysis and interpretation of the data, and helped to draft the manuscript.
PA participated in the study design, performed the statistical analysis and
assisted with interpretation of the data, and helped to draft the manuscript.
RT participated in the design and coordination of the study and helped to
draft the manuscript. SH participated in the design of the study and helped
to draft the manuscript. JG participated in the design of the study and
helped to draft the manuscript. NJ participated in the design of the study
and helped to draft the manuscript. AF participated in the design of the
study and helped to draft the manuscript. AW participated in the design of
the study and helped to draft the manuscript. KW participated in the study
design, assisted with study coordination and data collection, and critically
reviewed and revised the manuscript. SG assisted with study coordination
Resnicow et al. BMC Medical Informatics and Decision Making 2014, 14:110 Page 8 of 9
http://www.biomedcentral.com/1472-6947/14/110and data collection and critically reviewed and revised the manuscript. SK
assisted with the conceptualization and design of the study and with the
interpretation of the data and critically reviewed and revised the manuscript.
All authors read and approved the final manuscript.Acknowledgements
This work was funded by grant number P01 CA163233 from the National
Cancer Institute to the University of Michigan. We acknowledge the
outstanding work of the coordinators of the study sites: Imelda Burgan
(Memorial Sloan Kettering Cancer Center), Mackenzie Crawford (Emory
Midtown Hospital), and Anatasha Crawford (Grady Memorial Hospital).
Special thanks also to Rebecca Morrison (University of Michigan) and Greg
Powers (University of Michigan) for their assistance on the project.
Author details
1University of Michigan, School of Public Health, 109 Observatory Street, Ann
Arbor, MI 48109-2029, USA. 2University of Michigan, School of Medicine, 2800
Plymouth Road, Ann Arbor, MI 48109, USA. 3Veterans Administration, Ann
Arbor Center for Clinical Management Research, 2800 Plymouth Road,
Building 16, Rm. 421 W, Ann Arbor, MI 48109-2800, USA. 4Emory University,
Rollins School of Public Health, 1518 Clifton Road, NE, Atlanta, GA 30322,
USA. 5Department of Surgery, Emory University School of Medicine, Winship
Cancer Institute of Emory University, 69 Jesse Hill Jr. Dr. SE, Room 303,
Atlanta, GA 30303, USA.
Received: 29 July 2014 Accepted: 10 November 2014
References
1. Seror V, Cortaredona S, Bouhnik A-D, Meresse M, Cluze C, Viens P, Rey D,
Peretti-Watel P: Young breast cancer patients' involvement in treatment
decisions: the major role played by decision-making about surgery.
Psycho-Oncology 2013, 22:2546–2556.
2. Ashraf AA, Colakoglu S, Nguyen JT, Anastasopulos AJ, Ibrahim AMS, Yueh
JH, Lin SJ, Tobias AM, Lee BT: Patient involvement in the decision-making
process improves satisfaction and quality of life in postmastectomy
breast reconstruction. J Surg Res 2013, 184:665–670.
3. Mac Bride MB, Neal L, Dilaveri CA, Sandhu NP, Hieken TJ, Ghosh K, Wahner-
Roedler DL: Factors associated with surgical decision making in women
with early-stage breast cancer: a literature review. J Womens Health
(Larchmt) 2013, 22:236–242.
4. Obeidat R, Finnell DS, Lally RM: Decision aids for surgical treatment of
early stage breast cancer: A narrative review of the literature. Patient
Educ Couns 2011, 85:e311–e321.
5. Dillard AJ, Scherer L, Ubel PA, Smith DM, Zikmund-Fisher BJ, McClure JB,
Greene S, Stark A, Fagerlin A: Breast cancer anxiety's associations with
responses to a chemoprevention decision aid. Soc Sci Med 2013, 77:13–19.
6. Sheppard VB, Williams KP, Harrison TM, Jennings Y, Lucas W, Stephen J,
Robinson D, Mandelblatt JS, Taylor KL: Development of decision-support
intervention for Black women with breast cancer. Psycho-Oncology 2010,
19:62–70.
7. O’Brien MA, Whelan TJ, Charles C, Ellis PM, Gafni A, Lovrics P, Hasler A,
Dimitry S: Women's perceptions of their treatment decision-making
about breast cancer treatment. Patient Educ Couns 2008, 73:431–436.
8. O'Connor AM, Wennberg JE, Legare F, Llewellyn-Thomas HA, Moulton BW,
Sepucha KR, Sodano AG, King JS: Toward the 'tipping point': decision
aids and informed patient choice. Health affairs (Project Hope) 2007,
26:716–725.
9. Lee CN, Chang Y, Adimorah N, Belkora JK, Moy B, Partridge AH, Ollila DW,
Sepucha KR: Decision making about surgery for early-stage breast cancer.
J Am Coll Surg 2012, 214:1–10.
10. Lee CN, Hultman CS, Sepucha K: Do patients and providers agree about
the most important facts and goals for breast reconstruction decisions?
Ann Plast Surg 2010, 64:563–566.
11. Katz SJ, Belkora J, Elwyn G: Shared decision making for treatment of
cancer: challenges and opportunities. J Clin Oncol 2014, 10:206–208.
12. Sepucha K, Ozanne EM: How to define and measure concordance
between patients' preferences and medical treatments: A systematic
review of approaches and recommendations for standardization.
Patient Educ Couns 2010, 78:12–23.13. Fowler FJ Jr, Gallagher PM, Drake KM, Sepucha KR: Decision Dissonance:
Evaluating an Approach to Measuring the Quality of Surgical Decision
Making. Jt Comm J Qual Patient Saf 2013, 39:.
14. Fowler FJ Jr, Levin CA, Sepucha KR: Informing and involving patients to
improve the quality of medical decisions. Health affairs (Project Hope)
2011, 30:699–706.
15. Stalmeier PF, Roosmalen MS: Concise evaluation of decision aids. Patient
Educ Couns 2009, 74:104–109.
16. Sepucha KR, Belkora JK, Chang Y, Cosenza C, Levin CA, Moy B, Partridge A, Lee CN:
Measuring decision quality: psychometric evaluation of a new instrument for
breast cancer surgery. BMC Med Inform Decis Mak 2012, 12:51.
17. Hawley ST, Lantz P, Janz NK, Salem B, Schwartz K, Liu L, Deapen D, Morrow
M, Katz SJ: Factors associated with patient involvement in surgical
treatment decision making for breast cancer. Patient Educ Couns 2007,
65:387–395.
18. Kokufu H: Conflict accompanying the choice of initial treatment in breast
cancer patients. Jpn J Nurs Sci 2012, 9:177–184.
19. Bieber C, Muller KG, Nicolai J, Hartmann M, Eich W: How does your doctor talk
with you? Preliminary validation of a brief patient self-report questionnaire
on the quality of physician-patient interaction. J Clin Psychol Med Settings
2010, 17:125–136.
20. Halkett GKB, Arbon P, Scutter SD, Borg M: The experience of making
treatment decisions for women with early stage breast cancer: a
diagrammatic representation. Eur J Cancer Care 2005, 14:249–255.
21. Kreling B, Figueiredo MI, Sheppard VL, Mandelblatt JS: A qualitative study of
factors affecting chemotherapy use in older women with breast cancer:
barriers, promoters, and implications for intervention. Psycho-Oncology 2006,
15:1065–1076.
22. Belkora JK, Volz S, Teng AE, Moore DH, Loth MK, Sepucha KR: Impact of
decision aids in a sustained implementation at a breast care center.
Patient Educ Couns 2012, 86:195–204.
23. Sepucha K, Ozanne E, Silvia K, Partridge A, Mulley AG Jr: An approach to
measuring the quality of breast cancer decisions. Patient Educ Couns
2007, 65:261–269.
24. Sepucha KR, Fagerlin A, Couper MP, Levin CA, Singer E, Zikmund-Fisher BJ:
How does feeling informed relate to being informed? The DECISIONS
survey. Med Decis Making 2010, 30:77S–84S.
25. Fagerlin A, Sepucha KR, Couper MP, Levin CA, Singer E, Zikmund-Fisher BJ:
Patients' knowledge about 9 common health conditions: the DECISIONS
survey. Med Decis Making 2010, 30:35S–52S.
26. Elwyn G, Miron-Shatz T: Deliberation before determination: the definition
and evaluation of good decision making. Health Expect 2010, 13:139–147.
27. Sepucha KR, Borkhoff CM, Lally J, Levin CA, Matlock DD, Ng CJ, Ropka ME,
Stacey D, Joseph-Williams N, Wills CE, Thomson R: Establishing the
effectiveness of patient decision aids: key constructs and measurement
instruments. BMC Med Inform Decis Mak 2013, 13 Suppl 2:S12.
28. Elwyn G, O'Connor AM, Bennett C, Newcombe RG, Politi M, Durand MA, Drake
E, Joseph-Williams N, Khangura S, Saarimaki A, Sivell S, Stiel M, Bernstein SJ, Col
N, Coulter A, Eden K, Harter M, Rovner MH, Moumjid N, Stacey D, Thomson R,
Whelan T, van der Weijden T, Edwards A: Assessing the quality of
decision support technologies using the International Patient Decision Aid
Standards instrument (IPDASi). PLoS One 2009, 4:e4705.
29. Mancini J, Santin G, Chabal F, Julian-Reynier C: Cross-cultural validation of
the Decisional Conflict Scale in a sample of French patients. Qual Life Res
2006, 15:1063–1068.
30. O'Connor AM: Validation of a decisional conflict scale. Med Decis Making
1995, 15:25–30.
31. Holmes-Rovner M, Kroll J, Schmitt N, Rovner DR, Breer ML, Rothert ML,
Padonu G, Talarczyk G: Patient satisfaction with health care decisions: the
satisfaction with decision scale. Med Decis Making 1996, 16:58–64.
32. Deci E, Ryan R: Intrinsic motivation and self-determination in human behavior.
New York: Plenum; 1985.
33. Deci E, Ryan R: The "what" and "why" of goal pursuits: Human needs and
the self-determination of behavior. Psychol Inq 2000, 11:227–268.
34. Vansteenkiste M, Williams GC, Resnicow K: Toward systematic integration
between self-determination theory and motivational interviewing as
examples of top-down and bottom-up intervention development:
autonomy or volition as a fundamental theoretical principle. Int J Behav
Nutr Phys Act 2012, 9:23.
35. Lantz PM, Janz NK, Fagerlin A, Schwartz K, Liu L, Lakhani I, Salem B, Katz SJ:
Satisfaction with surgery outcomes and the decision process in a
Resnicow et al. BMC Medical Informatics and Decision Making 2014, 14:110 Page 9 of 9
http://www.biomedcentral.com/1472-6947/14/110population-based sample of women with breast cancer. Health Serv Res
2005, 40:745–767.
36. Hawley ST, Lillie SE, Morris A, Graff JJ, Hamilton A, Katz SJ: Surgeon-level
variation in patients' appraisals of their breast cancer treatment
experiences. Ann Surg Oncol 2013, 20:7–14.
37. Hitz F, Ribi K, Li Q, Klingbiel D, Cerny T, Koeberle D: Predictors of
satisfaction with treatment decision, decision-making preferences, and
main treatment goals in patients with advanced cancer. Support Care
Cancer 2013, 21:3085–3093.
38. Molenaar S, Sprangers MA, Rutgers EJ, Luiten EJ, Mulder J, Bossuyt PM,
van Everdingen JJ, Oosterveld P, de Haes HC: Decision support for patients
with early-stage breast cancer: effects of an interactive breast cancer
CDROM on treatment decision, satisfaction, and quality of life.
J Clin Oncol 2001, 19:1676–1687.
39. Zhong T, Hu J, Bagher S, O'Neill AC, Beber B, Hofer SO, Metcalfe KA: Decision
regret following breast reconstruction: the role of self-efficacy and
satisfaction with information in the preoperative period. Plast Reconstr Surg
2013, 132:724e–734e.
40. Waljee JF, Hawley S, Alderman AK, Morrow M, Katz SJ: Patient satisfaction
with treatment of breast cancer: does surgeon specialization matter?
J Clin Oncol 2007, 25:3694–3698.
41. Berry DL, Ellis WJ, Russell KJ, Blasko JC, Bush N, Blumenstein B, Lange PH:
Factors That Predict Treatment Choice and Satisfaction with the
Decision in Men with Localized Prostate Cancer. Clin Genitourin Cancer
2006, 5:219–226.
42. Hoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL: Patient
satisfaction with treatment decisions for clinically localized prostate
carcinoma. Results from the Prostate Cancer Outcomes Study.
Cancer 2003, 97:1653–1662.
doi:10.1186/s12911-014-0110-x
Cite this article as: Resnicow et al.: Development and psychometric
properties of a brief measure of subjective decision quality for breast
cancer treatment. BMC Medical Informatics and Decision Making
2014 14:110.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
